Drugs / APL-1501
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06435039 | Jun → Jul 2024 | — | Syneos Health | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06034015 Comparator | Sep 2023 → Jan 2024 | urinary bladder cancer | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-1501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06034015 ↗ |
| Route | Oral | “Participants will receive APL-1202 375 milligram (mg) IR tablets, orally, once on Day 1 of Period 1 (Treatment R1), followed by T1 APL-1501 764 mg ER capsules, orally, once, on...” NCT06435039 ↗ |